Home Featured Page 214

Featured

Latest

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

PT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and Altered States of Consciousness Meet

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

Pharmacological Testing in Psychedelic Research

Catching Up with the Psychedelic Entourage Effect: Part 4 – CaaMTech

Ayahuasca’s Role in the Entourage Effect and Depression

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet...

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

1...213214215 Page 214 of 215

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation...

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks...

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

PT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and Altered States of Consciousness Meet

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

Pharmacological Testing in Psychedelic Research

Catching Up with the Psychedelic Entourage Effect: Part 4 – CaaMTech

Ayahuasca’s Role in the Entourage Effect and Depression

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet...

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

EDITOR PICKS

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation...

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks...

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

POPULAR CATEGORY